Asymptomatic replication of human herpesviruses (HHV) is frequent in HIV-infected men and is associated with increased Tcell activation and HIV disease progression. We hypothesized that the presence of replication of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) (the most frequently detected HHV) might influence HIV DNA decay during antiretroviral therapy (ART). We investigated 607 peripheral blood mononuclear cell (PBMC) samples from 107 CMV-seropositive, HIV-infected men who have sex with men, who started ART within a median of 3 months from their estimated date of infection (EDI) and were monitored for a median of 19 months thereafter. Levels of HIV, CMV, and EBV DNA and cellular HIV RNA were measured by droplet digital PCR (ddPCR) for each time point. Using a general linear mixed-effect regression model, we evaluated associations between the presence of detectable CMV DNA and EBV DNA levels and HIV DNA decay and cellular HIV RNA levels, while adjusting for peak HIV RNA, nadir CD4
Replication of Human Herpesviruses Is Associated with
T he long-lived latent HIV reservoir that persists during suppressive antiretroviral therapy (ART) is the major obstacle in achieving a cure (1). Two possible mechanisms underlying HIV persistence during suppressive ART include residual HIV replication (2, 3) and proliferation of latently infected CD4 ϩ T cells (4) . Further, chronic inflammation and immune activation modulate both HIV replication and T-cell proliferation and contribute to the maintenance of the HIV DNA reservoir even during ART (5) (6) (7) . Similar to the case with HIV, asymptomatic replication of human herpesviruses (HHV) also mediates immune activation (8) (9) (10) . This can be important since subclinical bursts of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are common among HIV-infected individuals, even those with high CD4 ϩ T-cell counts and those receiving effective ART (11) . Given that most HIV-infected individuals and almost all HIV-infected men who have sex with men (MSM) are coinfected with multiple HHV (12) and persistent viral replication is a known driver of immune activation, we hypothesized that CMV, and possibly EBV, drives activation and proliferation of latently infected CD4 ϩ T cells and plays a role in the maintenance of the HIV DNA reservoir during ART.
In a cross-sectional study of HIV-infected individuals who started ART during chronic infection, we previously observed that asymptomatic shedding of CMV in the male genital tract was associated with increased systemic T-cell immune activation and proliferation and with higher levels of HIV DNA in peripheral
CD4
ϩ T cells (10, 14) . This cross-sectional study had a number of limitations which may have confounded the analysis, including the lack of longitudinal data and missing information about timing of HIV infection, ART history, and dynamics of viral suppression. Additionally, since the HIV DNA reservoir is established during the earliest stages of HIV infection, it may be particularly important to evaluate people who initiated ART during primary HIV infection. To address these issues, in this study we measured levels of CMV, EBV, and HIV DNA, as well as cellular HIV RNA transcripts, longitudinally in peripheral blood mononuclear cells (PBMC) of 107 HIV-infected individuals who started ART within the first months of HIV infection and achieved continuous HIV RNA suppression for up to 75 months.
MATERIALS AND METHODS
Participants, samples, and clinical laboratory tests. A total of 607 blood samples were collected longitudinally from 107 recently HIV-infected CMV-seropositive participants from the San Diego Primary Infection Resource Consortium (15) between October 1996 and October 2012. Most participants (81%) started ART within the first year of HIV infection, and all participants achieved complete suppression of HIV RNA (defined as Ͻ50 HIV RNA copies/ml) and maintained undetectable HIV RNA levels in blood plasma for a median of 19.2 months. The estimated date of infection (EDI) was calculated using established algorithms (16) . Longitudinal blood samples were collected during suppressive ART at approximately 6-month intervals (n ϭ 515), while pre-ART blood samples were available for a subset of 92 participants. In blood, percentage and absolute counts of CD4 ϩ T lymphocyte subsets were measured by flow cytometry (VA Flow Lab) and HIV-1 RNA was quantified (Amplicor HIV Monitor test; Roche Molecular Systems Inc.). All adult subjects provided their written informed consent. No children were included in this study. The Office of Human Research Protections Program of the University of California approved the study.
HIV DNA, 2-LTR circular HIV DNA, CMV DNA, and EBV DNA in PBMC. DNA was extracted from 5 million PBMC for each time point using the AllPrep DNA/RNA minikit (Qiagen, CA). Total HIV DNA (polymerase [Pol] ) and the 2-long terminal repeat (2-LTR) junction were quantified by droplet digital PCR (ddPCR) from extracted DNA (17) . Briefly, 1,000 ng of DNA per replicate was digested with BSAJ1 enzyme (New England BioLabs) prior to ddPCR quantification. Total HIV DNA (Pol) and 2-LTR PCRs were performed as a duplex assay with VIC (Pol) and 6-carboxyfluorescein (FAM) (2-LTR) probes, respectively, with the following cycling conditions: 10 min of initial enzyme activation at 95°C, 40 cycles consisting of a 30-s denaturation at 94°C followed by a 60°C extension for 60 s, and a final inactivation of 10 min at 98°C. Total CMV and EBV DNA PCRs were performed as a duplex with FAM (CMV) and HEX (EBV), respectively, with the following cycling conditions: 10 min of initial enzyme activation at 95°C, 40 cycles consisting of a 30-s denaturation at 94°C followed by a 54°C extension for 60 s, and a final inactivation of 10 min at 98°C. We used the host cell RNase P/MRP 30-kDa-subunit gene (RPP30) as our cellular normalizer, as it appears in 2 copies per cell. The digested DNA was diluted 10-fold, and 100 ng of the digested DNA per replicate was used for quantification of RPP30 by ddPCR (probe VIC) and cycled with the same parameters as for the Pol/2-LTR duplex. Copy numbers were calculated as the mean of replicate PCR measurements and normalized to one million CD4 ϩ T cells as determined by RPP30 (total cell count) and flow cytometry (percentage of CD4 ϩ T cells) (18) . Cellular HIV RNA in PBMC. Cellular HIV RNA was extracted from PBMC using the AllPrep DNA/RNA minikit (Qiagen, CA) by following the manufacturer's protocol, with addition of a DNase step to avoid DNA contamination (RNase-free DNase Set, Qiagen, CA). Extracted RNA (500 ng) was reverse transcribed into 20 l of cDNA (iScript Advanced cDNA synthesis kit; Bio-Rad) using the manufacturer's protocol. The cDNA product (8 l; approximately 300 ng) was added to the ddPCR mixture.
Unspliced HIV RNA (usRNA) (Gag) and multiply spliced HIV RNA (msRNA) (Tat/Rev) PCRs were performed as a duplex with HEX (usGag) and FAM (msTat/Rev) probes, respectively, using primers and probes as previously described (20) . Additionally, levels of all fully elongated and correctly processed HIV mRNA molecules (referred to as polyA) were measured as described previously (21) . Cycling conditions for this PCR were 10 min at 95°C, 60 cycles consisting of a 30-s denaturation at 94°C followed by a 60°C extension for 60 s, and a final 10 min at 98°C. Copy numbers were calculated as the means of replicate PCR measurements and normalized to total RNA as determined by A 260 /A 280 absorptivity ratio using a NanoDrop 2000 spectrophotometer (Thermo Scientific) (10) .
Anti-CMV IgG antibody levels. Anti-CMV IgG antibody levels were measured in blood plasma at baseline (pre-ART) and at week 48 after the initiation of ART. Units per milliliter were determined by interpolation from a standard curve of a known anti-CMV IgG solution, as previously described (22, 23) .
Statistical analysis. Since levels of CMV DNA were undetectable in 65% (n ϭ 337) of sampled time points, CMV DNA measurements were dichotomized as detectable or undetectable for this analysis. Additionally, since CMV shedding often occurs intermittently, participants who had at least one time point with a detectable level of CMV DNA during ART (n ϭ 69; 64.5%) were compared to participants without detectable CMV DNA at any time point (n ϭ 38; 35.5%). A common-log transformation of the longitudinal measures of HIV DNA was used to conform best to model assumptions of normality and homoscedasticity. Undetectable levels of HIV DNA (n ϭ 108; 21%) were replaced with a value just below the minimum level detected for our primary analysis (minimum value was 1.48 copies per 10 6 cells; replacement value was 1.4 copies per 10 6 cells). Since the continuous variables of time, peak HIV RNA, nadir CD4 ϩ , CD4/CD8 ratio, time from EDI to ART initiation, and time from ART initiation to virologic suppression lacked a linear relationship with HIV DNA levels, we transformed or dichotomized all of these covariates, including a log transformation of time and EBV DNA, classification of early ART initiation (Ͻ3 months of infection), and dichotomization of the remainder variables at their medians. Time points with missing CD4/CD8 ratios (n ϭ 24; 4.7%) were imputed using the mean of the previous and subsequent known values or the last known value carried forward.
Baseline characteristics and demographics were compared using Fisher's exact tests and Wilcoxon-Mann-Whitney tests. To assess the decline of HIV DNA over time between participants with and without CMV, we used linear mixed-effects regression analysis with random-subject intercepts. The primary fixed effects were detectable CMV DNA, time, and the interaction of CMV and time. The interaction term in the model tested whether the change (or decay) in HIV DNA levels over time was significantly different for participants with intermittent CMV DNA replication compared to those without any detectable CMV. With the inclusion of this interaction term in the model, the group effect (or CMV term) tested the difference in HIV DNA levels at baseline (at initiation of ART). We used the same modeling strategy to test the association of EBV DNA levels on HIV DNA during ART. In secondary analysis, we investigated the effects of the following covariates: peak HIV RNA level, nadir CD4 ϩ count, CD4/CD8 ratio, CMV IgG, time from EDI to the initiation of ART, time from the initiation of ART to viral suppression, presence of detectable CMV DNA pre-ART, and age.
Before introducing other covariates into the model, we tested the association between individual covariates and HIV DNA levels by building separate mixed-effects models for each covariate. Except for CMV and early initiation of ART, none of the interactions between covariates and time were significantly associated with HIV DNA in the individual models or in the final multivariable model, so only the results for the main effects are presented.
To evaluate the effect of the censored data for HIV DNA, we performed multiple sensitivity analyses and repeated our regression analysis (i) using half the minimum level detected (0.7 copies per 10 6 cells), (ii) performing a Tobit regression instead of a linear mixed-effects regression, and (iii) excluding time points with RPP30 levels below the 5th percentile (Ͻ13,440 copies/well). To evaluate for potential differences in HIV RNA transcription, we used a mixed-effects logistic regression model to investigate whether having detectable CMV DNA was associated with the presence of detectable cell-associated HIV usRNA (Gag), HIV msRNA (Tat/ Rev), polyA HIV RNA, or detectable 2-LTR circles. The association between the HIV RNA transcription variables and possible covariates were also investigated. , and half of our participants achieved viral suppression within 3.6 months (IQR, 1.8 to 5.5 months). Most were white, nonHispanic participants (65.1%) who had been infected less than 70 days before study enrollment (80.4%). At baseline (first post-ART time point), participants were a median of 35 years old, had a median CD4 ϩ T-cell count of 490 cells/l, and had a median of 5.4 log 10 HIV RNA copies/ml. In our analysis, we divided participants in two groups: those with intermittent CMV DNA in PBMC (n ϭ 69) and those without any detectable CMV DNA (n ϭ 38). Overall, characteristics were similar between the two groups (Table 1) , although as previously reported (23), individuals with CMV replication had lower levels of CMV IgG than did people with no CMV replication (median of 24.5 versus 30 IU/ml blood plasma [P ϭ 0.08]), and participants with CMV started ART a median of 2 months earlier than those without CMV (P ϭ 0.04).
RESULTS

Participants
Herpesvirus and HIV characteristics in PBMC before and after the initiation of ART. CMV and EBV DNA were detectable in 35% and 83% of the PBMC samples, respectively; 64.5% of the study participants had at least one time point with detectable CMV DNA during the follow-up period. Total levels of HIV DNA (Pol) as measured by ddPCR were detectable in 85% of the 92 pre-ART PBMC samples, with a median level of 2.6 log 10 copies per million CD4 ϩ T cells (IQR, 1.7 to 3.2), while 2-LTR circles were detectable in two-thirds of all pre-ART PBMC samples, with a median level of 1.7 log 10 copies per million CD4 ϩ T cells among detectable samples (IQR, 1.4 to 2.3). After the initiation of ART, HIV DNA was detectable in 79% of all 515 PBMC samples, with a median level of 1.7 log 10 copies per million CD4 ϩ T cells (IQR, 1.0 to 2.5), while 2-LTR circles were detectable in 53% of all PBMC samples, with a median level of 1.6 log 10 copies per million CD4 ϩ T cells among detectable samples (IQR, 1.2 to 2.1). HIV usRNA (Gag) was detectable in 96% of samples before ART initiation and 82% of samples during ART, HIV msRNA encoding Tat/Rev was detectable in 89% of samples before ART and 52% during ART, and poly(A) HIV RNA was detectable in 93% of samples before ART and 65% of samples during ART.
Individual covariate associations with HIV DNA levels. The results from the individual regressions of HIV DNA on each co- variate are presented in Table 2 . For each doubling of time on ART (i.e., months 1, 2, 4, 8, etc.), HIV DNA levels declined an average of 0.20 log 10 copy/10 6 CD4 ϩ T cells without adjusting for other effects. At baseline, there was no significant difference in the mean levels of HIV DNA for participants with CMV and participants without detectable CMV (P ϭ 0.095), but the mean level of HIV DNA for subjects with CMV declined significantly slower than for subjects with no detectable CMV (P ϭ 0.009). Specifically, for each doubling of month on ART, HIV DNA declined 0.13 log 10 copies/10 6 CD4 ϩ cells more slowly for people with detectable CMV DNA in their PBMC than for people without detectable CMV (Fig. 1) .
Similarly, higher EBV DNA levels were significantly associated with higher levels of HIV DNA (P Ͻ 0.001). In a separate model of HIV DNA regressed on EBV, time, and the interaction of EBV and time (not shown), the interaction term was not significantly associated with HIV DNA (P ϭ 0.393), indicating that EBV was not significantly associated with the change or decay in HIV DNA. Additionally, time points with CD4/CD8 ratios greater than the median (Ն1) were more likely to exhibit mean levels of HIV DNA approximately 0.5 log 10 copies/10 6 CD4 ϩ cells lower (Ͻ0.001). No other examined variable had a significant association with the decline in HIV DNA over time when considered individually. Also, pre-ART CMV, early initiation of ART (Ͻ3 months), nadir CD4, age, and CMV IgG did not have a significant association with the mean levels of HIV DNA during ART.
Multivariable model of HIV DNA levels. In our multivariable model, HIV DNA levels declined significantly more slowly (i) for participants with detectable CMV than for those with undetectable CMV DNA (P Ͻ 0.011) and (ii) for participants who did not initiate ART within 3 months of infection than for those with early initiation of ART (P ϭ 0.012). Specifically, for each doubling of months on ART (2, 4, 8, 16 , etc.), the adjusted level of HIV DNA declined 0.12 log 10 copy slower for participants with detectable CMV DNA compared to those with no detectable CMV, with all other characteristics being equal. This represented about double the rate of decline in HIV DNA levels for participants with no detectable CMV (0.23 versus 0.11 log 10 copy/10 6 CD4 ϩ T cells for each doubling of months on ART [ Fig. 1 and 2] ). In comparison, HIV DNA levels declined 0.08 log 10 copies/10 6 CD4 ϩ T cells faster for each doubling of months on ART for participants who started ART within 3 months of infection than for people who started ART later. There was a significant interaction between low CD4/CD8 ratios and EBV levels (P ϭ 0.006), meaning that EBV levels also affected HIV DNA levels differently in the presence of low or high CD4/CD8 ratios. Specifically in stratified analysis, higher EBV levels were significantly associated with higher levels of HIV DNA (P Ͻ 0.001) in the presence of low CD4/CD8 ratios (Ͻ1), but not when CD4/CD8 ratios were high (Ն1) (P ϭ 0.145).
In the subset of 92 participants with pre-ART measurements of HIV DNA, we investigated how adjusting for the pre-ART level of HIV DNA influenced the observed associations between detectable CMV and HIV DNA levels. In this analysis, participants with higher pre-ART levels of HIV DNA presented significantly higher HIV DNA levels at baseline (P Ͻ 0.001)and had a faster decrease in HIV DNA levels on ART (P ϭ 0.004). When pre-ART levels of HIV DNA were included in the model, baseline HIV DNA levels were not different between the CMV and non-CMV groups (P ϭ 0.25) and HIV DNA levels still declined significantly more slowly, by 0.10 log 10 copy for participants with detectable CMV during ART (P ϭ 0.033).
To evaluate the effect of the censored data for HIV DNA, we performed three sensitivity analyses (as described under "Statistical analysis" above), and in all cases we confirmed the significant associations between detectable CMV and decay rate of HIV DNA levels (P value using half the minimum level detected ϭ 0.016; P values using a Tobit regression ϭ 0.017; P value excluding time points with RPP30 levels below the 5th percentile ϭ 0.021). Finally, we investigated whether frequency of detectable CMV had an effect on HIV DNA levels. In this analysis, the longitudinal change in HIV DNA levels was similar for participants who had detectable CMV in 1 to 50% or Ͼ50% of the included time points (P ϭ 0.598 [ Fig. 2]) , and both groups presented slower HIV DNA decay than did the no-CMV group. Associations between detectable CMV and EBV DNA, cellular HIV RNA, and 2-LTR circles. To evaluate possible mechanisms of slower HIV DNA decay in the detectable-CMV group, mixed-effects logistic regression models were used to investigate the associations between detectable levels of CMV DNA during ART and cellular HIV msRNA (Tat/Rev), HIV usRNA (Gag), polyA HIV RNA, and 2-LTR HIV DNA circles. In this analysis, detectable CMV during ART was not significantly associated with levels of HIV msRNA (P ϭ 0.934), usRNA (P ϭ 0.755), polyA HIV RNA (P ϭ 0.064), or 2-LTR circles (P ϭ 0.809). In a similar model, higher levels of EBV during ART were significantly associated with higher levels of HIV usRNA (P ϭ 0.010) but not with msRNA (P ϭ 0.138), polyA HIV RNA (P ϭ 0.070), or 2-LTR circles (P ϭ 0.448). Independent of viral infections, lower CD4/CD8 ratios (Յ1) and longer time to suppression were significantly associated with higher levels of polyA HIV RNA (P ϭ 0.001 and P ϭ 0.041, respectively). No other tested variable (CD4 count, peak HIV RNA level, or time on ART) was associated with increased levels of cellular HIV RNA transcription or 2-LTR circles.
DISCUSSION
The immunologic and virologic connections between HIV and HHV are intertwined and complicated, especially with the very prevalent HHV CMV and EBV (9, 24) . To better understand how asymptomatic CMV and EBV replication in blood cells is associated with HIV DNA levels over time, we investigated a large, uniquely well-characterized cohort of HIV-infected MSM who started ART during the early phases of HIV infection and sustained stable HIV RNA suppression. Overall, our study found that asymptomatic replication of CMV in PBMC was the strongest variable associated with lower rates of decay of the HIV DNA reservoir after the early initiation of ART. Further, detectable CMV in PBMC accounted for a 0.12-log 10 -slower HIV DNA decay for each doubling in months of follow-up between participants. The only other factor associated with slower HIV DNA decay rate was later initiation of ART. In fact, HIV DNA levels declined 0.08 log 10 copy/10 6 CD4 ϩ T cells faster for each doubling of months on ART in participants who started ART within 3 months from EDI than for those with a later ART start. Interestingly, higher baseline HIV DNA levels before ART and detectable EBV DNA were both associated with increased HIV DNA levels during suppressive ART but not with HIV DNA decay over time. Further, higher levels of EBV DNA were associated with greater HIV DNA levels only when the CD4/CD8 ratio was lower than 1, suggesting that a conserved immune system might be protective against the EBV effect on HIV DNA levels. A similar interaction was not present between CMV and CD4/CD8 ratio.
Although the current study design does not allow causality to be inferred, it does support the theory that persistent CMV replication at low levels could contribute to the stability of the HIV DNA reservoir during suppressive ART even when ART is initiated during the earliest phases of HIV infection. The observed association between higher HIV DNA levels and presence of detectable EBV DNA could suggest that coinfection with HHV in general might contribute to HIV persistence. Through millions of years of coexistence, HHV have developed numerous strategies to modulate the human immune response, including impeding antigen-reactive immune cells from eradicating virus-infected cells (24) . It is reasonable to hypothesize that other coinfecting pathogens, like HIV, could exploit this particular immune environment to promote HIV pathogen persistence and replication, for example, through upregulation of immune-inhibitory molecules like interleukin 10 (IL-10) and programmed cell death protein 1 (PD-1), which are also involved in HIV persistence (25, 26) . Persistence of the HIV DNA reservoir during ART has been attributed to two possible factors, which could contribute separately or in combination. First, residual or intermittent HIV RNA replication replenishes the pool of infected cells over time (2, 3) . Second, HIV-infected cells undergo homeostatic or antigendriven proliferation (4). To investigate possible mechanisms underlying the connection between presence of CMV DNA and slower HIV DNA decay, we investigated if the presence of CMV DNA was associated with higher levels of cellular HIV RNA or more detectable 2-LTR circles during ART, suggesting increased residual HIV RNA replication. We found no association between the presence of cellular CMV DNA and any HIV RNA transcription or with detectable 2-LTR circles. Highlighting differences between blood and other mucosal sites (i.e., genital), this study differed from our previous cross-sectional study of chronically HIV-infected individuals (10) , in which the presence of genital CMV DNA replication was associated with higher levels of HIV msRNA but not HIV usRNA. While this difference might be a consequence of different cohorts and sampling strategies, the consistent lack of association between CMV DNA and HIV usRNA in both studies suggests that a different mechanism likely connects asymptomatic CMV replication and HIV persistence. An alternative explanation connecting CMV and HIV persistence might be an increase in antigen-driven or bystander clonal expansion of HIV-infected lymphocytes. Also, the relationship between CMV replication and slower HIV decay might be that CMV enhances the infection of longer-lived cell types (like central memory cells), which decay more slowly than effector T cells (27) . Both these hypotheses need to be tested in future studies. On the other hand, high levels of EBV DNA were associated with increased HIV us-RNA, suggesting that EBV might be associated with increased HIV transcription during suppressive ART.
This study had a number of limitations. Most importantly, because this was an observational study, we cannot establish a definitive causal relationship between CMV and EBV reactivation and HIV DNA levels, and the extent of immune activation during treated HIV infection could be a determinant of both HHV shedding and slower HIV DNA decay. Similarly, slower HIV DNA decay might be the cause of increased CMV shedding. However, participants with and without CMV replication presented similar baseline characteristics, including peak HIV RNA, pre-ART HIV DNA levels, and rates of EBV DNA replication in PBMC, arguing against generalized inflammation within the detectable-CMV group.
It is not clear if the observed increase in HIV DNA levels in CD4 ϩ T cells represents replication-competent latent provirus or which cellular subset carries the integrated HIV DNA in relation to detectable CMV DNA. While previous work suggested that CMV-specific cells are not preferentially infected with HIV DNA, compared to HIV-infected cells (28, 29) , their relative contribution to the maintenance of the HIV reservoir during long-term suppressive ART has not been evaluated. It is conceivable that continuous stimulation of a CMV-specific immune response by persistent subclinical replication (while HIV RNA is suppressed with ART) might lead to a preferential expansion of these populations. Alternatively, bystander inflammation (often seen during CMV infection) (24) could sustain a proliferation of HIV-infected CD4 ϩ T cells or enhanced infection of longer-lived cell types (27) . It is also not clear if the presence of detectable CMV DNA in PBMC is a surrogate of low-level CMV replication or just latent CMV DNA present in circulating monocytes. Another limitation is that our study only evaluated levels of cellular HIV RNA transcription in PBMC, and we cannot exclude that a difference in cellular transcription might exist in another compartment (e.g., lymph tissue).
Despite these limitations, this study provides important insights regarding connections between asymptomatic HHV replication and the HIV DNA levels and complements our previous findings by providing longitudinal data on a well-characterized cohort of individuals during early HIV infection. Specifically, it demonstrated that even among individuals who started ART early during HIV infection, asymptomatic CMV reactivation was associated with slower HIV DNA decay. Additionally, it demonstrated that this effect was not unique to CMV but might be also associated with detection of EBV, although the mechanisms are likely different. Since almost all HIV-infected individuals and especially HIV-infected MSM are infected with multiple HHV (12) , future studies are needed to determine if persistent CMV and EBV replication could be targeted as a strategy to reduce the size of the latent HIV reservoir. Further, since our study only evaluated CMV and EBV, future studies should evaluate if other persistent coinfecting viruses might also promote HIV DNA persistence.
